Literature DB >> 1321832

Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in Escherichia coli.

K W Harris1, R A Mitchell, J C Winkelmann.   

Abstract

We developed an assay to directly measure the ligand binding properties of the cloned human erythropoietin receptor (EpoR). The cDNA encoding the extracellular domain of the human EpoR was amplified by polymerase chain reaction and ligated into the prokaryotic expression vector pGEX3X. Synthesis in Escherichia coli was induced and a soluble glutathione S-transferase fusion protein, EREx, was purified by erythropoietin affinity chromatography. Purified EREx was bound to GSH agarose beads and used in a solid phase ligand binding assay. Specific binding of 125I-erythropoietin to EREx beads was demonstrated. A single affinity class (Kd = 1.5 nM) of the binding site was evident on Scatchard analysis. The Kd of this site is quantitatively equivalent to that of the "low" affinity cellular binding site. Kinetic analysis of ligand binding to EREx revealed both the on and off rates to be rapid, with t1/2 of 60 and 40 s, respectively. EREx ligand binding exhibits no obvious metal ion dependence or cross-competition by other hemopoietins. Antibodies to EREx block the binding of erythropoietin to the cellular EpoR. We conclude that the 66-kDa EpoR protein is capable of specific ligand binding and that no covalent modifications or associated molecules are required for this interaction. We speculate that the "high" affinity cellular binding site (Kd less than 0.2 nM) results from the interaction of the EpoR with another molecule, either additional EpoR or associated subunits, that decreases the ligand off rate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321832

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells.

Authors:  S Laquerre; D B Anderson; D B Stolz; J C Glorioso
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

2.  Chimeric tumor necrosis factor receptors with constitutive signaling activity.

Authors:  F Bazzoni; E Alejos; B Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

3.  Recombinant Human erythropoietin reduces viability of MCF-7 breast cancer cells from 3D culture without caspase activation.

Authors:  Hareth Y ShujaaEdin; Nagi A Al-Haj; Abdullah Rasedee; Noorjahan Banu Alitheen; Arifah Abdul Kadir; Chee Wun How; Heshu Sulaiman Rahman; Al-Shwyeh Hussah Abdullah
Journal:  Saudi J Biol Sci       Date:  2021-02-11       Impact factor: 4.219

4.  Optimisation of chemical protein cleavage for erythropoietin semi-synthesis using native chemical ligation.

Authors:  Jonathan P Richardson; Derek Macmillan
Journal:  Org Biomol Chem       Date:  2008-09-05       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.